Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

cent in this year's second quarter to $34.8 million from $25.1 million in the same quarter a year ago. This growth is being driven by the expanded U.S. sales force for Seprafilm(R) adhesion barrier, which is helping to expand the product's use in gynecologic and colorectal surgery and C-section procedures.

Second-quarter revenue for the Genetics business increased 7 percent to $78.5 million from $73.7 million. This growth was driven in part by the continuing demand for prenatal screening for genetic conditions. Additionally, Genzyme experienced increased demand for its KRAS mutation testing for colorectal cancer, as recent studies have shown that identifying KRAS mutations can assist oncologists in selecting treatment for patients with colorectal cancer. This increasing recognition of the value of diagnostics in personalized medicine will continue to fuel organic growth in the Genetics business.

Oncology revenue rose in the second quarter to $33.3 million from $17.4 million based on increasing sales of Clolar and Campath(R) (alemtuzumab). The increase also reflects the addition of European sales of Clolar, which Genzyme began recording following its acquisition of Bioenvision Inc. late last year. Genzyme is working to introduce Clolar worldwide as well as expand its indications. The product is currently approved in the United States and Europe as a third-line treatment for pediatric patients with acute lymphoblastic leukemia. Genzyme is developing Clolar for use globally as a first-line therapy for adult AML and myelodysplastic syndromes, significantly larger indications that the company estimates will drive peak annual sales of the product to approximately $600 million. Last month, Genzyme reported encouraging results from its pivotal CLASSIC II trial evaluating the use of Clolar to treat older adult patients with acute myeloid leukemia. Oncology revenue also reflects growing first-line use of Campath in the treatment of patients with B-cell chronic l
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... research platform uses a laser to measure ... stress and heating, an approach likely to ... and batteries., This new technique, called nanomechanical ... and the surface stress of microscale structures ... the merits of surface-stress influence on mechanical ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
(Date:8/28/2014)... Woodstock, Vt. (PRWEB) August 28, 2014 ... microbiology testing around the world is available from ... industrial diagnostics companies. “ Industrial Microbiology Market Review, ... the Industrial Market ” (IMMR—4) tracks and compares ... in in North America, Europe and Asia, and ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
... July 15 Amsterdam,Molecular Therapeutics (Euronext: AMT), a ... announced the start of a collaboration with St. ... the development,of a gene therapy treatment for Hemophilia ... commercial rights to the final product. The,combination of ...
... A report published in the July 8 issue of ... Sciences ( PNAS ) is the first to ... of tiny nanoclusters of metallic gold. The study, which ... the work of researchers at four universities on two ...
... HealthSonix, Inc.,(Pink Sheets: HSXI)(FWB:H7S) today announced that ... purchased two wholly owned,subsidiaries of HealthSonix, Inc. ... "Selling the two operating companies to Innovative ... the companies to,resume full operations and get ...
Cached Biology Technology:AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 2AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 4Study reveals principles behind stability and electronic properties of gold nanoclusters 2Study reveals principles behind stability and electronic properties of gold nanoclusters 3Study reveals principles behind stability and electronic properties of gold nanoclusters 4HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences 2
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research ... for the American College of Sports Medicine,s Conference ... 2014 in Miami, Florida. These awards are ... doctorates and scientists from underrepresented groups into the ... encourage the participation of young scientists at the ...
(Date:8/28/2014)... PA, August 28, 2014 Dyslexia, the most ... is a neurological reading disability that occurs when ... language don,t function normally. , The use of ... brain activity is disrupted in dyslexia. However, most ... number of brain regions, leaving a gap in ...
(Date:8/28/2014)... and mould in homes could pose a significant health risk ... in the Journal of Allergy and Clinical Immunology . ... eight different countries, the research has found that the presence ... in asthma sufferers, as well as increasing the likelihood of ... a team at the University of Exeter Medical School and ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2
... HOUSTON -- (Aug. 16, 2010) -- A new ... and other human activity has completely obscured the natural ... "The natural factors that influence carbon dioxide cycling ... the radiocarbon signature of the river to reflect those ...
... of some of the most repugnant smells on earth, but ... has a sense of smell of its own. A team ... first time that bacteria have a molecular "nose" that is ... today in Biotechnology Journal , their study shows how ...
... infrared laser can make a heart beat faster. Scientists ... pulsed light can pace contractions in an avian embryonic heart, ... pacing of the embryonic heart," will be published in the ... 15, 2010. According to the scientists, this non-invasive device ...
Cached Biology News:A river flipped: Humans trump nature on Texas river 2A river flipped: Humans trump nature on Texas river 3Bacteria breakthrough is heaven scent 2A heart beats to a different drummer 2
... BODIPY FL ATP-Gamma-S binds to ... nucleotide the BODIPY FL fluorophore was ... In addition to its potential use ... ATP-Gamma-S thioether is an important new ...
... world of discovery races ever faster, you need ... fast track. So our constant focus is on ... research. Thats why our Biomek 3000 Laboratory Automation ... advanced as it is flexible. By integrating all ...
... Pro is the industry standard microarray image ... of imaging and analysis tools, visualizations, automation ... Pro is included with every GenePix scanner, ... third-party scanners and all types of arrays. ...
... 60 rabbit tissue samples arrayed on Superfrost Plus ... and 1 hematoxylin and eosin (H&E) stained slide ... tissues from 4 rabbit organisms, for a total ... sample (or core) is 1.5 mm in diameter. ...
Biology Products: